Mutated EGFR-IN-1

• CAT Number: I001620
• CAS Number: 1421372-66-8
• Molecular Formula: C25H31N7O
• Molecular Weight: 445.56
• Purity: ≥95%
• Synonyms: N1-(2-(dimethylamino)ethyl)-5-methoxy-N1-methyl-N4-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)benzene-1,2,4-triamine
• Target: EGFR
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IUPAC Name: 1-N-[2-(dimethylamino)ethyl]-5-methoxy-1-N-methyl-4-N-[4-(1-methylindol-3-yl)pyrimidin-2-yl]benzene-1,2,4-triamine
• InChI: InChI=1S/C25H31N7O/c1-30(2)12-13-31(3)23-15-24(33-5)21(14-19(23)26)29-25-27-11-10-20(28-25)18-16-32(4)22-9-7-6-8-17(18)22/h6-11,14-16H,12-13,26H2,1-5H3,(H,27,28,29)
• InChIKey: HTNTZPBKKCORTP-UHFFFAOYSA-N
• SMILES: NC1=CC(NC2=NC=CC(C3=CN(C)C4=C3C=CC=C4)=N2)=C(OC)C=C1N(CCN(C)C)C

Mutated EGFR-IN-1 (Cat.No:I001620) is a small molecule inhibitor that targets the mutated form of epidermal growth factor receptor (EGFR). It is designed to specifically block the activity of mutated EGFR, which is often found in certain types of cancer. By inhibiting the aberrant signaling pathways associated with mutated EGFR, Mutated EGFR-IN-1 holds promise as a potential targeted therapy for cancer treatment.

Reference

[1]. Patent WO 2013014448 A1. 2 – (2, 4, 5 – substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer .